Wegovy and a Racing Heart: Separating Fact from Fear

The assumption most people make, and why it's only half the story

The most common thing people assume when they feel their heart racing on Wegovy is that something must be going wrong with their heart. That worry is understandable, but it misses what the clinical picture actually shows. A modest increase in heart rate is a documented pharmacological effect of GLP-1 receptor agonists as a class (semaglutide included) and it appears in the medicine's licensed labelling precisely because it is expected, not because it signals danger. The NHS medicines page for semaglutide lists a faster heartbeat among the recognised side effects of treatment.

That said, the assumption isn't entirely wrong either. There is a spectrum. For most people, what they feel is a mild elevation: the heart beats slightly faster at rest, especially in the weeks after starting or after a dose increase, and then settles. For others, the sensation is more pronounced, a pounding or fluttering that feels hard to ignore. Knowing which category you're in matters, and that distinction is something a clinician is best placed to make. Dismissing all fast heartbeats as trivial would be as inaccurate as treating every one as a crisis.

The underlying mechanism is that GLP-1 receptors are present in cardiac tissue. Activating them has autonomic effects, including a sympathetic influence on heart rate. This isn't unique to semaglutide; it's a class-level finding seen across this group of medicines. How Wegovy interacts with cardiac physiology is a topic our clinical team covers in more depth if you want the full mechanistic picture.

What the trial data shows about heart rate changes on semaglutide

In the STEP 1 trial (the pivotal phase-three study of semaglutide 2.4mg, published in the New England Journal of Medicine) a small but consistent increase in resting heart rate was observed in participants taking semaglutide compared with placebo. The mean increase was modest, typically in the range of five beats per minute. Most participants did not find this clinically meaningful. It did not translate into a higher rate of serious cardiac events in the trial population.

The picture with Wegovy's higher 7.2mg dose is being studied actively, but the current evidence base suggests the heart-rate effect scales only modestly with dose. Clinical trials for this dose class reported around 20.7% average weight loss over 72 weeks, a significant therapeutic gain that, for most people with obesity, has net cardiovascular benefit over time, since obesity itself is a major driver of heart disease. That longer-term context matters when weighing a small, transient rise in heart rate against sustained weight reduction.

If you are specifically wondering about how Wegovy affects resting heart rate across different doses, that page goes further into the numbers. And if your concern is specifically about palpitations happening when you're sitting still, palpitations at rest on Wegovy covers that pattern separately.

When a racing heart on Wegovy needs medical attention

Most of the time, a mild increase in pulse rate during Wegovy treatment is self-limiting. It often peaks in the first few weeks and fades without any change to your dose. The NHS notes that heart-related symptoms should be taken seriously when they are severe, sudden, or come alongside other warning signs.

Get same-day medical help (call 999 or go to A&E) if a fast or pounding heartbeat is accompanied by chest pain or tightness, breathlessness, dizziness, fainting, or a feeling that something is seriously wrong. These combinations can indicate a cardiac arrhythmia or another condition that has nothing to do with Wegovy and needs urgent assessment.

Contact your prescriber or GP within a day or two (rather than waiting for a routine appointment) if your heart rate stays elevated for more than a couple of weeks, if palpitations are frequent and interfering with daily life, or if you have a pre-existing heart condition. A simple resting ECG can rule out most rhythm abnormalities quickly. You can also report suspected side effects directly to the MHRA through the Yellow Card scheme, this benefits future patients by adding to the post-market safety record.

For context on the broader relationship between this medicine and heart health, Wegovy's cardiovascular evidence base covers the SELECT trial findings and what they mean for people with obesity.

Practical steps while you're waiting to speak to someone

If your heart is racing after a recent dose increase, log when it happens: time of day, what you were doing, whether it came on suddenly or built gradually. This information is genuinely useful to your prescriber. Dehydration makes palpitations more noticeable, and Wegovy-related nausea can reduce how much people drink, so keeping fluid intake up matters. Caffeine amplifies the sensation for some people; cutting back temporarily is a low-risk thing to try.

Avoid stopping Wegovy abruptly without speaking to your prescriber first. A dose pause or adjustment can be made clinically, but the decision belongs to your prescriber, not to a moment of anxiety. If you haven't yet started treatment and you're wondering whether Wegovy can cause a racing heart before you begin, that page addresses the pre-treatment question directly.

Wegovy is a prescription medicine, which means clinical support is built into legitimate treatment. If you're on treatment through nume, our prescribers are available seven days a week. If questions like this arise between doses, our support team can connect you quickly. For anyone still exploring whether treatment is right for them, a free consultation with our prescribers is the right starting point, they can discuss your cardiac history as part of the full clinical assessment, and if you are pregnant or planning a pregnancy, our page on using Wegovy during pregnancy sets out the current guidance on safety and alternatives.